(19)
`
`(12)
`
`European Patent Office
`Office europeen des brevets
`
`^ ^ ^ ^ I ^ ^ ^ ^ ^ ^ II ^ II ^ ^ ^ II ^ ^ ^ ^ ^ ^ ^ ^ ^ I ^
`
`E P 0 2 3 5 7 9 6 B 2
`
`NEW EUROPEAN PATENT S P E C I F I C A T I O N
`
`(51) mtci.6: C07D 313/12, C07D 405/06,
`C07D 405/12, A61K 3 1 / 3 3 5
`
`(45) Date of publication and mention
`of the opposition decision:
`12.03.1997 Bulletin 1997/11
`
`(45) Mention of the grant of the patent:
`06.05.1992 Bulletin 1992/19
`
`(21) Application number: 87102983.1
`
`(22) Date of filing: 03.03.1987
`
`(54) Dibenz [b,e] oxepin derivative and antiallergic and antiinflammatory agent
`Dibenzo[b,e]oxepin-Derivate sowie antiallergische und entzundunghemmende Mittel
`Derives de dibenzo[b,e]oxepine et agent anti-allergique et anti-inflammatoire
`
`(84) Designated Contracting States:
`BE CH DE ES FR GB IT LI NL
`
`(30) Priority: 03.03.1986 JP 45676/86
`
`(43) Date of publication of application:
`09.09.1987 Bulletin 1987/37
`
`(73) Proprietor: KYOWA HAKKO KOGYO CO., LTD.
`Chiyoda-ku, Tokyo (JP)
`
`(72) Inventors:
`• Oshima, Etsuo
`c/o KYOWA HAKKO KOGYO CO., LTD
`Chiyoda-ku Tokyo (JP)
`• Kumazawa, Toshiaki
`c/o KYOWA HAKKO KOGYO CO., LTD
`Chiyoda-ku Tokyo (JP)
`• Otaki, Shizuo
`c/o KYOWA HAKKO KOGYO CO., LTD
`Chiyoda-ku Tokyo (JP)
`• Obase, Hiroyuki
`c/o KYOWA HAKKO KOGYO CO., LTD
`Chiyoda-ku Tokyo (JP)
`• Ohmori, Kenji
`c/o KYOWA HAKKO KOGYO CO., LTD
`Chiyoda-ku Tokyo (JP)
`• Ishii, Hidee
`c/o KYOWA HAKKO KOGGYO CO., LTD
`Chiyoda-ku Tokyo (JP)
`
`• Manabe, Haruhiko
`c/o KYOWA HAKKO KOGYO CO., LTD
`Chiyoda-ku Tokyo (JP)
`• Tamura, Tadafumi
`c/o KYOWA HAKKO KOGYO CO., LTD
`Chiyoda-ku Tokyo (JP)
`• Shuto, Katsuichi
`c/o KYOWA HAKKO KOGYO CO., LTD
`Chiyoda-ku Tokyo (JP)
`
`(74) Representative: Casalonga, Axel et al
`BUREAU D.A. CASALONGA - JOSSE
`Morassistrasse 8
`80469 Miinchen (DE)
`
`(56) References cited:
`EP-A- 214 779
`EP-A-0 069 810
`EP-A- 0 1 88 802
`GB-A- 1 018 995
`
`EP-A- 0 038 564
`EP-A- 0 130 555
`GB-A- 1 003 950
`US-A-3 509 176
`
`JOURNAL OF MEDICINAL CHEMISTRY, vol. 21,
`no. 7, July 1978, pages 633-639, American
`Chemical Society; "Novel arabinofuranosyl
`derivatives of cytosine resistant to enzymatic
`deamination and possessing potent antitumor
`activity"
`
`Remarks:
`The file contains technical information submitted
`after the application was filed and not included in this
`specification
`
`Printed by Jouve, 75001 PARIS (FR)
`
`CM
`DO
`CO
`O)
`Is-
`i o
`CO
`CM
`o
`a .
`LU
`
`APOTEX EX1032
`
`Page 1
`
`

`
`EP 0 235 796 B2
`
`Description
`
`Background of the Invention
`
`Heretofore, it has been known that 11-unsubstituted, 11 -hydroxy or 11-oxodibenz[b,e]oxepin derivative is used for
`antiinflammatory agents [J. Med. Chem., 21_, 633 - 639 (1978)].
`Further, it is known that dibenz[b,e]oxepin derivative wherein substitutents Ra and Rb at 11 -position have the
`following definitions, is employed in the treatment and control of allergic conditions (USP 4.282.365).
`
`Ra: H, CH, lower alkoxy, lower alkylthio, lower alkylsulfinyl, lower alkylsulfonyl, arylthio, NH2, NHCHO or imidazolyl;
`
`Rb: H or lower alkyl;
`
`or Ra and Rb taken together are = 0, = CH-Rc wherein Rc is H or aryl.
`Furthermore, it is known that 11-(4-methylpiperazino) dibenz[b,e]oxepin derivative has an antiasthmatic activity
`(USP 4.396.550 USP 4.465,835, EP-A-38564).
`It is also known that dibenz[b,e]oxepin derivative having the following formula:
`
`S
`
`- - ' N
`
`wherein Rd and Re are lower alkyl and Rf is lower alkyl or halogen, has an antiasthmatic activity (EP-A-85870).
`Dibenz[b,e]oxepin derivative having an antiallergic activity and having the following structural formula:
`
`0- (CH2) r ^ g S h
`
`wherein Rg and Rh are alkyl, r is 2 or 3 and Ri is alkyl or halogen is known (JP-A-227879/84).
`Dibenz[b,e]oxepin derivative having an antiallergic activity and having the following structural formula:
`
`wherein Rj is 4-alkylpiperazino, 3-quinuclidylamino or -Xa-(CH2)s-NR€Rm wherein Xa is -NH-, -S- or -O-, s is 2 or 3
`and R€ and Rm are alkyl, and Rk is CN, 5-tetrazolyl, CONH2 or C02Rn wherein Rn is H, alkyl or 1 -(ethoxycarbonyloxy)
`ethyl is known (EP-A-1 30555).
`Doxepin having an antidepressant activity and having the following structural formula is known [Drugs, j_3. 161
`(1977)].
`
`Page 2
`
`

`
`EP 0 235 796 B2
`
`N (Me) 2
`
`Dothiepin having an antidepressant activity and having the following structural formula is known [Arz.-Forsch., 13
`1039 (1963); ibid., _14 100 (1964)].
`
`It is also known that dibenz [b,e] oxepin derivatives having the formula :
`
`Y
`
`wherein :
`
`R is hydrogen or methyl ;
`R1 is a lower alkyl, lower alkenyl or lower cycloalkyl ;
`X and Y are each hydrogen, lower alkyl, lower alkoxy, lower alkylthio, chloro, fluoro, trifluoromethyl, lower acyl or
`dialkylsulfonamido, have an antidepressent activity (GB 1,018,955).
`
`It is known that dibenz [b,e] oxepin derivatives of formula :
`
`wherein R5 is a single bond or -CH=CH-, have an anti-asthmatic activity (EP 214779).
`As the compound having both an anti-allergic activity and an anti-inflammatory activity, steroids are known.
`It is always desired that a novel compound having an antiallergic activity and an antiinflammatory activity be de-
`veloped.
`The present invention relates to a dibenz[b, e]oxepin derivative represented by the formula (I):
`
`3
`
`10
`
`15
`
`20
`
`25
`
`35
`
`40
`
`45
`
`so
`
`55
`
`Page 3
`
`

`
`EP 0 235 796 B2
`
`^ - ( C H ^ n - Z
`
`8
`
`Y-A
`
`(I)
`
`wherein
`
`A represents a carboxyl, a straight or branched (C-,-C6) alkoxy carbonyl group, -CONHOH or -CONR-1R2 wherein
`R-i and R2 are the same or different and represent hydrogen atom or a straight or a branched (C-,-C6) alkyl
`Y represents -(CH2)-, -CHR3-(CH2)m- wherein R3 represents a straight or branched (C-1-C4) alkyl, and m is 1, 2,
`3 or 4, which is the substituent at 2- or 3-position of the mother nucleus and the left side of the group Y is bound
`to benzene nucleus.
`X represents =N-, =CH-;
`n is o, 1 , 2, 3 or 4;
`Z represents 4-methylpiperazino, 4-methylhomopiperazino, piperidino, pyrrolidine, thiomorpholino, morpholino or
`-NR6R7 wherein R6 and R7 are the same or different and represent hydrogen atom or a straight or branched (C-,-
`C4) alkyl a — - means double bond; and the pharmaceutical^ acceptable salts thereof.
`
`The present invention further pertains to pharmaceutical composition containing an effective amount of Compound
`(I) or a pharmaceutical^ acceptable salt thereof as an active ingredient, and a carrier or an excipient.
`The present compound (I) is useful for treatment of allergic conditions and inflammation diseases.
`
`DETAILED DESCRIPTION OF THE INVENTION
`
`In the definition of each group of formula (I), the lower alkyl group includes straight or branched chain alkyl groups
`having 1 to 6 carbon atoms, for example, methyl, ethyl, n-propyl, iso-propyl, n-butyl, etc.
`In the definition of the group A, lower alkyl moiety of lower alkoxymethyl group and lower alkoxycarbonyl group
`has the same meaning as previously defined.
`The lower alkoxymethyl group includes methoxymethyl, ethoxymethyl, n-propoxymethyl, isopropoxymethyl, etc.
`and the lower alkoxycarbonyl group includes methoxycarbonyl, ethoxycarbonyl, etc.
`In the definition of the group A, the lower alkyl moiety of lower alkanoyl group and lower alkanyoloxymethyl group
`has the same meaning as previously defined.
`The lower alkanoyl group includes formyl, acetyl, etc. and the lower alkanoyloxymethyl group includes formylo-
`cymmethyl, acetyloxymethyl.
`The pharmaceutical^ acceptable salt of compound (I) includes pharmaceutical^ acceptable acid addition salt,
`metal salt, ammonium salt, organic amine addition salt, amino acid addition salt, etc..
`The pharmaceutical^ acceptable acid addition salt of compound (I) includes inorganic acid salts such as hydro-
`chloride, sulfate, phosphate, etc., and organic acid salts such as acetate, maleate, fumarate, tartrate, citrate, etc.. The
`pharmaceutical^ acceptable metal salt includes alkalimetal salts such as sodium salt, potassium salt, etc., alkaline
`earch metal salts such as magnesium salt, calcium salt, etc., and aluminium salt, zinc salt, etc.. The pharmaceutical^
`acceptable organic amine addition salt includes addition salt of morpholine and piperidine and the pharmaceutical^
`acceptable amino acid addition salt includes addition salt of lysine, glysine, phenylalanine, etc..
`Compound (I) is prepared by using a compound represented by the formula (II):
`
`0
`
`( II )
`
`wherein Y and A have the same meanings as previously defined or a compound represented by the formula (III):
`
`Page 4
`
`

`
`EP 0 235 796 B2
`
`wherein Y and A have the same meanings as previously defined as the starting compound. Compound (II) is disclosed
`in J. Med. Chem., 19. 941 (1976), ibid., 20, 1499 (1977) and J P-A-2 1679/83.
`Compound (III) wherein -Y-A is -COOH is disclosed in JP-A-21679/83 and the other Compounds (III) can be pre-
`pared according to the method described in the publication though they do not occur in the publication.
`The process for preparing Compound (I) is explained, depending on the kind of the group X.
`
`Process A
`
`[Synthesis of Compound (I) wherein X is = CH- (Part 1)]
`
`The carboxy group of Compound (I la) is protected according to the following reaction scheme.
`
`( V )
`
`In the formula, Y has the same meaning as previously defined, and Compound (I la) is included in Compound (II)
`(compounds with an alphabet suffix following formula number are likewise included in compounds with common formula
`no.)
`Compound (I la) is reacted with 1 to 5 equivalents of thionyl chloride and 1 to 5 equivalents of 2-amino-2-methyl-
`1- propanol on the basis of Compound (I la) in an inert solvent such as methylene chloride, if necessary in the presence
`of a base such as triethylamine at a temperature of from 0°C to room temperature for 1-24 hours to form Compound
`(IV). Compound (IV) can also be obtained by reacting Compound (I la) with thionyl chloride in advance and then with
`2- amino-2-methyl-1 -propanol.
`Compound (IV) is reacted with 1-5 equivalents of thionyl chloride in an inert solvent such as methylene chloride,
`toluene and benzene at a temperature of from 0°C to room temperature for I - 24 hours to form Compound (V).
`Compounds (la) and (lb) can be prepared from Compound (V) according to the following reaction scheme.
`
`Page 5
`
`

`
`EP 0 235 796 B2
`
`0
`
`( l b )
`
`In the formulae, Y, Z, and n have the same meanings as previously defined, R8 is hydrogen or a lower alkyl group,
`R'8 is a lower alkyl group and Hal is halogen.
`As used herein, the term lower alkyl has the same meaning as that of lower alkyl in each group of formula (I).
`Halogen includes chlorine, bromine and iodine.
`Compound (V) is reacted with I - 5 equivalents of Compound (VI) in an inert solvent such as tetrahydrofuran and
`diethyl ether under atmosphere of an inert gas such as nitrogen and argon to form Compound (VII). The reaction is
`carried out at a temperature of from 0°C to room temperature and is usually completed in I - 24 hours.
`Compound (VII) is reacted with I - 5 equivalents of thionyl chloride or phosphoryl chloride in an inert solvent such
`as methylene chloride in the presence of a base such as pyridine to form Compound (la). The reaction is carried out
`at a temperature of from 0°C to room temperature and is completed in I - 24 hours.
`Compound (la) is incubated in an alcohol containing water, such as aqueous methanol solution, in the presence
`of an appropriate acidic catalyst such as p-toluenesulfonic acid at a temperature of from room temperature to the boiling
`point of the solvent to form Compound (lb) wherein R8 is H. The reaction is completed in I - 24 hours.
`Compound (VII) is incubated in an alcohol R8'OH in the presence of an appropriate acidic catalyst such as p-
`toluenesulfonic acid at a temperature of from room temperature to the boiling point of the solvent to form Compound
`(lb) wherein R8 is a lower alkyl. The reaction is completed in I - 24 hours.
`
`Process B
`
`[Synthesis of Compound (I) wherein X is =CH- (Part 2)]
`
`The carboxy group of a compound represented by the formula (I la) can be converted to a lower alkoxymethyl
`group or a trityloxymethyl group according to the following reaction scheme.
`
`Page 6
`
`

`
`EP 0 235 796 B2
`
`5
`
`10
`
`15
`
`20
`
`25
`
`30
`
`35
`
`40
`
`45
`
`so
`
`. ( X I )
`
`In the formulae, Y has the same meaning as previously defined, R9 is a lower alkyl group and R9' is a trityl group
`or a lower alkyl group. The term lower alkyl has the same meaning as that of lower alkyl in each group in formula (I).
`Compound (I la) is reduced with I - 5 equivalents of lithium aluminium hydride in tetrahydrofuran at a temperature
`of from 0°C to room temperature for I - 24 hours to form Compound (VIII).
`Compound (VIII) is reacted with I - 5 equivalents of trityl chloride in pyridine at a temperature of from room tem-
`perature to 1 00°C for I - 24 hours to form Compound (IX).
`Compound (IX) is oxidized with I - 5 equivalents of an appropriate oxidizing agent such as potassium permanganate
`and pyridinium chlorochromate in an inert solvent such as methylene chloride and acetone to form Compound (XI)
`wherein Rg is trityl. The reaction is carried out at a temperature of from 0°C to the boiling point of the solvent and is
`completed in I - 24 hours.
`Compound (VIII) is incubated in an alcohol of Rg OH in the presence of an appropriate acidic catalyst such as
`sulfuric acid at a temperature of from room temperature to the boiling point of the solvent to form Compound (X). The
`reaction is usually completed in I - 24 hours.
`Compound (X) is oxidized with I - 5 equivalents of an appropriate oxidizing agent such as Jones reagent in an
`inert solvent such as acetone to form Compound (XI) wherein Rg' is a lower alkyl. The reaction is carried out at a
`temperature of from 0°C to the boiling point of the solvent and is usually completed in I - 24 hours.
`The compounds represented by the formulae (Ic) and (Id) and if desired, the compound represented by the formula
`(le) can be synthesized from Compound (XI) according to the following reaction scheme.
`
`7
`
`Page 7
`
`

`
`EP 0 235 796 B2
`
`0
`
`( I e )
`
`40
`
`45
`
`so
`
`55
`
`In the formulae. Y, Z, R9', n and Hal have the same meanings as previously defined.
`Compound (XI) is reacted with Compound (VI) which is Grignard reagent according to the same manner as in the
`reaction step from Compound (V) to Compound (VII) in Process A to form Compound (XII).
`Compound (XII) is subjected to reaction according to the same manner as in the reaction step from Compound
`(VII) to Compound (la) in Process A to form Compound (Ic).
`Compound (Ic) is incubated in a solvent containing water such as aqueous dioxane in the presence of an appro-
`priate acidic catalyst such as p-toluenesulfonic acid at a temperature of from room temperature to the boiling point of
`the solvent to form Compound (Id). The reaction is usually completed in I - 24 hours.
`Compound (Id) can also be obtained in one step by incubating Compound (XII) in a solvent containing water such
`as aqueous dioxane in the presence of an appropriate acidic catalyst such as sulfonic acid at a temperature of from
`room temperature to the boiling point of the solvent. The reaction is usually completed in I - 24 hours.
`If desired, Compound (Id) is oxidized with I - 5 equivalents of an appropriate oxidizing agent such as Jones reagent
`in an inert solvent such as acetone to form Compound (le). The reaction is carried out at a temperature of from 0°C to
`the boiling point of the solvent and is usually completed in I - 24 hours.
`
`8
`
`Page 8
`
`

`
`EP 0 235 796 B2
`
`Process C
`
`[Synthesis of Compound (I) wherein X is =CH- (Part 3)].
`
`0
`
`( I f )
`
`In the formulae, Y, Z, and n have the same meanings as previously defined. A' represents the groups falling within
`the definition of A but lower alkanoyl group.
`Compound (lib) is reacted with I - 5 equivalents of Compound (XIII) in an inert solvent such as tetrahydrofuran
`under atmosphere of an inert gas such as nitrogen and argon at a temperature of from 0°C to room temperature for I
`- 24 hours to form Compound (lf).
`Compound (XIII) which is ylide, can be prepared according to the method described in C.A. 63 16366a (1965).
`
`Ph,P + H a l ( C H - )
`
`, K a l
`
`+
`=. P h , P ( C H , ) ^ . H a l - H a l "
`
`(XIV)
`
`(XV)
`
`2I
`
`KHal
`
`'
`
`P h 3 P ( C H 2 ) n + 1 Z
`
`. K a l " • ( H H a l ) q
`(XVI)
`
`In the formulae, Hal, n and Z have the same meanings as previously defined and q is I or 2. Compound (XIV) is
`reacted with an equivalent of triphenylphosphine in toluene at reflux of the solvent for I - 24 hours to form Compound
`(XV).
`Compound (XV) is reacted with I - 5 equivalents of HZ in ethanol at reflux of the solvent for I - 24 hours and excess
`HZ is distilled away under reduced pressure. After the addition of I - 5 equivalents of HHal on the basis of Compound
`(XV), the mixture is incubated at a temperature of from 0°C to the boiling point of the solvent for I - 24 hours to form
`Compound (XVI) which is Wittig reagent.
`Compound (XVI) is treated with I - 2 equivalents of an appropriate base such as n-butyl lithium in an inert solvent
`such as tetrahydrofuran under atmosphere of an inert gas such as nitrogen and argon to form ylide (XIII). The reaction
`is carried out at -78°C ~ room temperature and is usually completed in I - 24 hours.
`
`9
`
`Page 9
`
`

`
`EP 0 235 796 B2
`
`Process D
`
`[Synthesis of Compound (I) wherein X is =CH- (Part 4)]
`
`f o r m a l d e h y d e
`Y - A + or p o l y m e r i z e d
`f o r m a l d e h y d e
`
`+• K2
`
`A c i d
`
`^
`
`0
`
`N
`
`^
`
`
`
`( i g )
`
`In the formulae, Y, Z and A have the same meanings as previously defined.
`The process is known as Prince reaction [New Experimental Chemical Course (Maruzen), Vol. 14, Synthesis and
`Reaction of Organic Compound III, page 1375 (1977)].
`Compound (III), I to 5 equivalents of formaldehyde and I to 5 equivalents of HZ are subjected to reaction in an
`inert solvent such as tetrachloroethane in the presence of an acid or reaction in an acid as such serving as a solvent
`under atmosphere of an inert gas such as nitrogen and argon to yield Compound (Ig).
`The formaldehyde or polymerized formaldehyde includes p-formaldehyde, trioxane, etc. The acid includes acetic
`acid, trichloroacetic acid, trifluoroacetic acid, etc. The reaction is carried out at a temperature of from room temperature
`to the boiling point of the solvent and is completed in I - 24 hours.
`Compound (II I) which is the starting material can be prepared according to the process described in J P-A-21 679/83,
`as shown below.
`
`0
`
`( l i b )
`
`( X V I I )
`
`That is, Compound (lib), I to 5 equivalents of methyltriphenylphosphonium bromide and I to 5 equivalents of n-
`butyl lithium on the basis of Compound (lib) are subjected to reaction in an inert solvent at from -78°C to room tem-
`perature for I to 5 hours to yield ylide (XVII) which is reacted with an equivalents of Compound (lib) in an inert solvent
`at from -78°C to room temperature under atmosphere of an inert gas for I to 24 hours to yield Compound (Ilia).
`The inert gas includes nitrogen, argon, etc. and the inert solvent includes tetrahydrofuran, etc.
`The group A' in Compound (Ilia) can easily be converted to a lower alkanoyl group and therefore, Compound (III)
`can easily be prepared.
`
`10
`
`20
`
`25
`
`30
`
`35
`
`so
`
`10
`
`Page 10
`
`

`
`EP 0 235 796 B2
`
`Process E
`
`[Synthesis of Compound (I) wherein X is = N-]
`
`0
`
`( Ih )
`
`Compound (lib) and I to 10 equivalents of Compound (XVIII) are subjected to reaction in an inert solvent such as
`benzene in the presence of I to 10 equivalents of titanium tetrachloride at from 0°C to the boiling point of the solvent
`under atmosphere of an inert gas such as nitrogen and argon for I to 48 hours to yield Compound (Ih).
`Table 1 shows examples of Compound (I) or pharmaceutical^ acceptable salts thereof and Table 2 shows the
`structural formula thereof.
`
`11
`
`Page 11
`
`

`
`EP 0 235 796 B2
`
`Fable 3 shows characteristic signals in NMR and Table 4 shows retention time in HPLC.
`
`A
`
`X
`
`■x
`
`it
`
`$
`
`b
`
`Methyl c i s - 1 1 - ( 3 - d i j n e t h y l a m i n o p - r o p y l i c e n e ) -
`6 , 1 1 - d i h y d r o d i b e n z { b , e ] o x e p i n r 2 - a c e t a t e
`t r a n s - 1 1 - ( 3 - d i r c e t h y l a i a i n o p r o p y l i c e . n e ) -
`Methyl
`6, 1 1 - d i h y d r o d i b e n z l b , e ] o x e i 5 i n - 2 - a c e t a t e
`
`E t h y l c i s - 1 1 - ( 3 - d i m e t h y X a m i n o p r o p y l i d e r . e ) -6 , 1 1 -
`d i h y d r o d i b e n z [ b , e ] o x e 3 i n - 2 - a c e t a t e
`
`t r a n s - 1 1 - ( 3 - d i m e t h y l a m i n o p r o p y l i c e n e ) -
`E t h y l
`6 , 1 1 - d i h y d r o d i b e n z [o, e] o x e p i n - 2 - a c e t a t e
`
`C i s - 1 1 - ( 3 - d i m e t h y i a m i n o p r o p y l i d e n e ) -6, 1 1 -
`d i h y d r o d i b e n z [ b / e ] o x e p i n - 2 - a c e t i c a c i d
`
`T r a n s - 1 1 - ( 3 - e i m e t h y l a m i n c p r o p y i i d e n e > -6 , 1 1 -
`d i h y c r c d i b e n z i b , e ] o x e p i n - 2 - a c e t i c a c i d
`
`Methyl c i s r l l - ( 4 - d i m e t h y l a m i n o b u t y l i d e n e ) -6 , 1 1 -
`d i h y d r o d i b e n z [ b , e ] o x e p i n - 2 - a c e t a t e
`
`t r a n s - 1 1 - ( 4 - d i . u e t h y l a m i n o b u t y l i d e n e ) -
`Methyl
`6, 1 1 - d i h y d r o d i b e n z [ b , e ] o x e p i n - 2 - a c e t a t e
`
`C i s - 1 1 - ( 4 - d i m e t h y l a m i n o b u t y l i d e n e ) -6 , 1 1 -
`d i h y d r o d i b e n z ( b , e ) o x e p i n - 2 - a c e t i c a c i d
`T r a n s - 1 1 - ( 4 - d i m e t h y l a m i n o b u t y l i d e n e ) -6, 1 1 -
`d i h y d r o d i b e n z [ b , e ] o x e p i n - 2 - a c e t i c a c i d
`
`Methyl c i s - 1 1 - ( 3 - p y r r o l i d i n o p r o p y l i d e n e ) -6, 1 1 -
`d i h y d r o d i b e n z [b , e ] o x e p i n - 2 - a c e t a t e
`t r a n s - 1 1 - ( 3 - p y r r o l i d i n o p r o p y l i c e n e ) -
`Methyl
`6 , 1 1 - d i h y d r o d i b e n z [b,e] o x e p i n - 2 - a c e t a t e
`
`12
`
`Page 12
`
`

`
`EP 0 235 796 B2
`
`C i s - 1 1 - ( 3 - p y r r o l i d i n o p r o p y l i c e . n e ) -6 , 1 1 -
`d i h y d r o d i b e n z {b, e ] o x e p i n - 2 - a c e t i c a c i d
`T r a n s - 1 1 - ( 3 - p y r r o l i d i n o p r o p y l i d e n e ) - 6 t l l -
`d i h y d r o d i b e n z [ b , e ] o x e p i n - 2 - a c e t i c a c i d
`
`Methyl c i s - 1 1 - (2- ( 4 - m e t h y l p i p e r a z i n o ) -
`e t h y l i d e n e > 6 , l l - d i h y d r o d i b e n 2 { b , e ) o x e p i n - 2 -
`a c e t a t e
`
`t r a n s - 1 1 - (2- ( 4 - m a t h y l p i p e r a . z ' i n o ) -
`Methyl
`e thy lideneT-6 , 1 1 - d i h y d r o d i b e n z lb, e.J o x e p i n - 2 -
`-J
`a c e t a t e
`
`C i s - 1 1 - (2- ( 4 - : n e t h y l p i p e r a z i n o > - e t h y l i d e n e J -
`6 , l l - d i h y d r c d i b e . n z [ b , e ] o x e o i h - 2 - a c e t i c a c i d
`7
`T r a n s - 1 1 - [2- ( 4 - m e t h y l p i p e r a z i n o ) - e t h y l i d e n e f -
`6 , 1 1 - d i h y d r o d i b e n z [b, e J o x e p i n - 2 - a c e t i c acfc
`
`J
`
`Methyl c i s - 1 1 - ( 3 - d i m e t h y l a m i n o p r o p y l i d e n e ) -
`6 , 1 1 - d i h y d r o d i b e n z (b, e ] o x e p i n - 3 - a c e t a t e
`t r a n s - 1 1 - ( 3 - d i m e t h y l a m i n o p r o p y l i d e n e ) -
`Methyl
`6 , 1 1 - d i h y d r o d i b e n z (b, e] o x e p i n - 3 - a c e t a t e
`
`C i s - 1 1 - ( 3 - d i m e t h y l a r a i n o p r o p y l i d e n e ) -6, 1 1 -
`d i h y d r o d i b e n z [ b , e J o x e p i n - 3 - a c e t i c a c i d
`
`T r a n s - 1 1 - ( 3 - d i m e t h y l a m i n o p r o p y l i d e n e ) -6, 1 1 -
`j d i h y d r o d i b e n 2 ( b , e ] o x e ? i n - 3 - a c e t i c a c i d
`
`s
`
`*
`
`w
`
`3
`
`Page 13
`
`

`
`EP 0 235 796 B2
`
`S yvL
`1
`-11- ( 2 - d i : n e t h y l a m i n c e t h y l ) irair.c-
`Methyl
`1 S , l l - d i / w c r o d i b e n z tb, e) oxeoin- 2 - a c e t a t e
`Methyl anti-11- (2 -dimethyl amine ethyl) inir.o-
`6 , 11-dihydrodibe.nz [b, e] oxepin- 2 - a c e t a t e
`
`-11- ( 2 - d i - i e t h y l a n i n o e t h y l ) in\ino-6f 11-
`dihydrcdibenz [b, e] o x e t > i n - 2 - a c e t i c a c i d
`Anti-11- (2-di.T7.ethyla.'ninoethyl ) imino-S , 11-
`dihydrodibenz [b, e] oxepin- 2 - a c e t i c a c i d
`
`.-11- ( 2 - d i e t h y l a n i n o e t h y l ) inir.o-6, 11-
`Methyl
`dihydrodibe.nz [ b , e ] o x e p i n - 2 - a c e t a t e
`Methyl anti-11- (2-diethyla.-nincet.hyl) imino-
`6 , l l - d i h y d r o d i b e n 2 ( b , e ] o x e o i . - i - 2 - a c e t a t e
`
`-11- {2-ciethyla.-aincetr.yl ) inino- 6 , 11-
`dihycrodibe.nz [b, e ] o x e p i . n - 2 - a c e t i c acid
`Anti-11- ( 2 - d i e t h y l a n i n c e t h y l ) inir.o-6, 11-
`dihydrcdibenz | b , e ] c x e p i n - 2 - a c e t i c a c i d
`
`j
`:
`
`•
`|
`■
`|
`
`j
`|
`i
`i
`j
`!
`
`u
`
`^
`
`j/j
`
`w
`
`15
`
`20
`
`OR
`
`JU
`
`IS
`
`14
`
`Page 14
`
`

`
`EP 0 235 796 B2
`
`'
`
`16
`
`— — —
`<-=f*
`i-ll- (3-dix«thylininopropyl) imir.o-
`Methyl
`6,11-dihvdrodibenz [b, e ] oxepin- 2 -ac« t a t t
`Methyl anti-11- i3-dim«thylaainopropyl/ imino-
`6, 11-dihydrodibenz |b, a ] oxepin-2-ace t a t a
`
`1-11- (3-dijB€thylajainroropyl) inino-6 , 11-
`dihydrodibanz (b,aJoxepin-.*-acatic a c i d
`Anti-11- (3-dinethyla:ninopropyl) isiir.o- 6, 1 1-
`dihydrodibanz {b, e ] o x a p i n - 2 - a c e t i c a c i d
`
`Methyl c i n - 2 - [ l l - ( 2 - d i a e t h y l a j n l n o * J t i * y n a a i n o -
`6,11-dihydrodibanz [b, a] oxa^in-2-yl J - p r o p i o n a t e
`MethyT **Ttl-2- (11- f2-di;aethylaniinoethyl) iinino-
`i , .ii-dihydrodib«nz (b, a] oxepin-2-yl] - p r o p i o n a t e
`•
`-2- (11- (2-di=ethyla.Tiinoethyl)i.-ainoT«s,-ari-
`dihydxodib«nz (b, e]oxeoin-2-yLJ»prooionic acid
`Anti-2- (llrJ2— dl_setnylaaincathyl) iraino-6, 11-
`dikydrooibenz ( b , e ] o x e p i n - 2 - y l ] - p r o p i o n i c acid
`
`i-ll- (2-diaethylar\inoethyl) L-aino-6 , 11-
`Mathyl
`dihydrodibenz [b, a] oxepin- 3-&cetate
`Ma thy 1 anti-11- (2-dijr.ethylajainoethyl) i n i n o -
`S, 11-dihydrodibenz [b, e ] oxepin- 3 -ace tat a
`
`...i-ll- (2-dinethylaninoethyl ) imino-S , 11-
`dihydrodibenz [ b , e ] o x e p i n - 3 - a c e t i c a c i d
`Anti-11- (2-diraethylaninoethyl) imi.io-6 , 11 -
`dihydrocibenz (b, e ] oxepin- 3-acetic * c i d
`
`l o
`
`■ 1 9
`
`20
`
`21
`
`15
`
`Page 15
`
`

`
`EP 0 235 796 B2
`
`r-yn
`- 1 1 - ( 2 - c: -e - r. j 1
`-.cpr.pyl ) i.-rn.-.c-
`:
`y.e
`£,ll-'I:hycrcciher, z [ b , e ] c . - < e p : n - 3 - a c e t 2 t e
`.:er.hv 1 anti -11- ( 3-ci.-e thy larai. -.c propyl ) i m i n c -
`5 , i l - _ i h y d r c d i b e n z [ b , e ] o x e p i . - . - 3 - _ c e t a t e
`_____
`• 11- ( 3-cimethylar.ir.opropyl ) inino-6, 11-
`cihycrodibenz [b,e] oxepin- 3-acetic a c i d
`Anti-11- n-cinethyi-.Tiir.oprcpyl) imino-6 , 1 1 -
`c i h y c r o d i b e n z [ b , e ] o x e p i n - 3 - a c e t i c a c i d
`
`11- (3-Dinethylar.i.-.opropylirsne) -2- M , 4-
`d i . - e t h y l - 2 - o x a z o l i n _ - 2 - y l ) -5 , 1 1 - d i h y d r o c i b e r . z -
`[b.ejoxepin
`
`22
`
`23
`
`24
`
`25
`
`,
`
`■
`
`26
`
`27
`
`28
`
`Methyl cis-11- (B-aethyla.'ainoprooylidene) -6 , 11-
`dihydrodibenz [b, e] o x e p i n - 2 - a c e t a t e
`Methyl trans-11- (3-methyl_._inopropylide.ne)-
`6 , 11-dihydrodibenz (b,e. o x e p i n - 2 - a c e t a t e
`
`Cis-11- (3-.nethylajBincpropylider.e. -6, 11-
`dihydxodibenz (b, e] o x e o i n - 2 - a c e t i c a c i d
`Trans-11- (3-._ethylai_inopropylidene) -6 , 11-
`dihydrodibenz [ b , e ] o x e p i n - 2 - a c e t i c a c i d
`
`Methyl cis-11- ( 3 - a n i n o p r c p y l i d e n e ) - 6 , 1 1 -
`dihycrocibenz [b, e) oxepin- 2 - a c e t a t e
`Methyl trans-11- (3-aminoprcpylidene) -6 , 11-
`dihydrcdibenz [b, e] o x e p i n - 2 - a c e t a t e
`
`Cis-11- (3-aninopropylidene) -6 , 11-dihycrodibe.nz-
`( b , e ] o x e p i n - 2 - a c e t i c a c i d
`Trans -11- ( 3 - a a i n o p r o p y l i d e n e ) -6 ,11-
`dihydrcdibenz |b, e J oxepin- 2-ace tic a c i d
`
`3
`Pujr.arate • 3/2 hydrate of Con-.pour.d
`(trans form
`9
`Puna rat a • 2/3 hydrate of Compound
`(trans rem
`
`Sodium salt
`
`1 hydrate of Compound 19
`"(anti fdnn
`
`95%)
`
`88%)
`
`99%)
`
`16
`
`IU
`
`3i>
`
`Page 16
`
`

`
`10
`
`20
`
`25
`
`30
`
`35
`
`40
`
`45
`
`50
`
`55
`
`EP 0 235 796 B2
`
`Table 2
`
`_-(CH2}n-2
`jL
`^
`
`
` — Y-A
`
`^
`�
`
`Me
`?h
`Et
`
`: methyl group
`:
`phenyl- group
`:
`ethyl group
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`CH
`
`2-CK-COCMe
`
`- ^ \ ^ - S . M e _
`
`"
`
`"
`
`"
`
`"
`
`"
`
`"
`
`"
`
`"
`
`"
`
`"
`
`2-CH.CCOEt
`
`2-CH-COOH
`
`2-CH.COC:-.e
`
`2-CH-COCH
`2
`
`2-CH.COOMe
`
`2-CH?2COCH
`
`2-CH-COOMe
`
`2-CH.COOH
`
`3-CH2COCJ.a
`
`3-CH2CCOH
`
`2-CH,COOMe
`
`2-CH2COOH
`
`^"s^
`
`NMe_
`
`" ^ ^ \ ^ )
`
`-
`
`j
`~-N^ XXe
`
`j
`
`j
`
`*^~\^ NMe_
`
`17
`
`Page 17
`
`

`
`EP 0 235 796 B2
`
`„
`
`.
`
`2-CH2COCHe
`
`2-CH2COOH
`
`2-CH2COOMe
`
`2-CH.COOH
`
`■lCH2,n-2
`
`N - t -
`
`^ \ ^ ^
`
` sy.e2
`
`2-CH(C3-)COOMe
`
`2-CH(CH3JCOOK
`
`NHe2
`
`3-CH2COC.-!e
`
`3-CH-COOH
`
`3-CH2C00Me
`
`3-CH2CCCH
`
`- - " n - ^ HXe2
`
`..
`A
`
`N
`
`"
`
`"
`
`*
`
`"
`
`"
`
`"
`
`"
`
`-
`
`"
`
`Co-._cur.d
`No.
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`2Q
`
`21
`
`22
`
`23
`
`'24
`
`CH
`
`| 2 ^ 0 -
`
`1
`
`^ N